Five-year Survival of Patients with Late-stage Prostate Cancer: Comparison of the Military Health System and the U.S. General Population

Overview

Journal Br J Cancer

Specialty Oncology

Date 2023 Jan 7

PMID 36609596

Authors

Jie Lin

Darryl Nousome

Jiji Jiang

Gregory T Chesnut

Craig D Shriver

Kangmin Zhu

Affiliations

Soon will be listed here.

Abstract

Background: While the 5-year survival rate for local and regional prostate cancer is nearly 100%, it decreases dramatically for advanced tumours. Accessibility to health care is an important factor for cancer prognosis. The U.S. Military Health System (MHS) provides universal health care to its beneficiaries, reducing financial barriers to medical care. However, whether the universal care translates into improved survival among patients with advanced prostate cancer in the MHS is unknown. In this study, we compared the MHS and the U.S. general population in survival of patients with advanced prostate cancer (stages III and IV).

Methods: The MHS patients (N = 5379) were identified from the Department of Defense's (DoD) Automated Central Tumor Registry (ACTUR). Patients in the U.S. general population (N = 21,516) were identified from the Surveillance, Epidemiology, and End Results (SEER) programme. The two populations were matched on age, race, and diagnosis year.

Results: The ACTUR patients exhibited longer 5-year survival than the matched SEER patients (HR = 0.74, 95% CI = 0.67-0.83), after adjustment for the potential confounders. The improved survival was observed for ages 50 years or older, both White patients and Black patients, all tumour stages and grades. This was also demonstrated despite the receipt of surgery or radiation treatment.

Conclusions: MHS beneficiaries with advanced prostate cancer had longer survival than their counterparts in the U.S. general population.

Citing Articles

The Influence of β-Carotene and Its Liposomal Form on the Expression of EMT Markers and Androgen-Dependent Pathways in Different Prostate Cell Lines.

Dulinska-Litewka J, Dykas K, Boznanski S, Halubiec P, Kaczor-Kaminska M, Zagajewski J Antioxidants (Basel). 2024; 13(8).

PMID: 39199148 PMC: 11351549. DOI: 10.3390/antiox13080902.

Military service and health-related quality of life among gay and bisexual prostate cancer survivors: Results from the study.

Bates A, Mitteldorf D, Rosser B, Wheldon C, Polter E, Ross M BMJ Mil Health. 2024; .

PMID: 38548328 PMC: 11436476. DOI: 10.1136/military-2023-002649.

CPT1A mediates the succinylation of SP5 which activates transcription of PDPK1 to promote the viability and glycolysis of prostate cancer cells.

Liu S, Chen X, Zhang L, Lu B Cancer Biol Ther. 2024; 25(1):2329372.

PMID: 38494680 PMC: 10950282. DOI: 10.1080/15384047.2024.2329372.

Versatile Design of Organic Polymeric Nanoparticles for Photodynamic Therapy of Prostate Cancer.

Ling J, Gu R, Liu L, Chu R, Wu J, Zhong R ACS Mater Au. 2024; 4(1):14-29.

PMID: 38221923 PMC: 10786136. DOI: 10.1021/acsmaterialsau.3c00060.

References

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Walker G, Grant S, Guadagnolo B, Hoffman K, Smith B, Koshy M . Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol. 2014; 32(28):3118-25. PMC: 4876335. DOI: 10.1200/JCO.2014.55.6258. View

Lee J, Wang X, Ojha R, Johnson K . The effect of health insurance on childhood cancer survival in the United States. Cancer. 2017; 123(24):4878-4885. DOI: 10.1002/cncr.30925. View

Aizer A, Falit B, Mendu M, Chen M, Choueiri T, Hoffman K . Cancer-specific outcomes among young adults without health insurance. J Clin Oncol. 2014; 32(19):2025-30. PMC: 4879691. DOI: 10.1200/JCO.2013.54.2555. View

Ward E, Fedewa S, Cokkinides V, Virgo K . The association of insurance and stage at diagnosis among patients aged 55 to 74 years in the national cancer database. Cancer J. 2010; 16(6):614-21. DOI: 10.1097/PPO.0b013e3181ff2aec. View

Halpern M, Ward E, Pavluck A, Schrag N, Bian J, Chen A . Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008; 9(3):222-31. DOI: 10.1016/S1470-2045(08)70032-9. View

Slatore C, Au D, Gould M . An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes. Am J Respir Crit Care Med. 2010; 182(9):1195-205. DOI: 10.1164/rccm.2009-038ST. View

Wu X, Lund M, Kimmick G, Richardson L, Sabatino S, Chen V . Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol. 2011; 30(2):142-50. DOI: 10.1200/JCO.2011.36.8399. View

Krimphove M, Cole A, Fletcher S, Harmouch S, Berg S, Lipsitz S . Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2018; 22(1):125-136. DOI: 10.1038/s41391-018-0083-4. View

10.

Mahal A, Mahal B, Nguyen P, Yu J . Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer. 2017; 124(4):752-759. DOI: 10.1002/cncr.31106. View

11.

Mahal B, Aizer A, Ziehr D, Hyatt A, Lago-Hernandez C, Chen Y . The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis. 2014; 17(3):273-9. DOI: 10.1038/pcan.2014.23. View

12.

Ru Y, Liu J, Fantacone-Campbell J, Zhu K, Kovatich A, Hooke J . Comparative Survival Analysis of Invasive Breast Cancer Patients Treated by a U.S. Military Medical Center and Matched Patients From the U.S. General Population. Mil Med. 2017; 182(11):e1851-e1858. DOI: 10.7205/MILMED-D-17-00097. View

13.

Lin J, Bytnar J, Theeler B, McGlynn K, Shriver C, Zhu K . Survival among patients with glioma in the US Military Health System: A comparison with patients in the Surveillance, Epidemiology, and End Results program. Cancer. 2020; 126(13):3053-3060. PMC: 8477613. DOI: 10.1002/cncr.32884. View

14.

Negoita S, Feuer E, Mariotto A, Cronin K, Petkov V, Hussey S . Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer. 2018; 124(13):2801-2814. PMC: 6005761. DOI: 10.1002/cncr.31549. View

15.

Wong A, Rineer J, Schwartz D, Becker D, Safdieh J, Osborn V . Effect of Thoracic Radiotherapy Timing and Fractionation on Survival in Nonmetastatic Small Cell Lung Carcinoma. Clin Lung Cancer. 2016; 18(2):207-212. DOI: 10.1016/j.cllc.2016.07.009. View

16.

Barry M . Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med. 2001; 344(18):1373-7. DOI: 10.1056/NEJM200105033441806. View

17.

Wang M, Spiegelman D, Kuchiba A, Lochhead P, Kim S, Chan A . Statistical methods for studying disease subtype heterogeneity. Stat Med. 2015; 35(5):782-800. PMC: 4728021. DOI: 10.1002/sim.6793. View

18.

Mahal B, Ziehr D, Aizer A, Hyatt A, Sammon J, Schmid M . Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol. 2014; 32(8):1285-91. DOI: 10.1016/j.urolonc.2014.04.014. View

19.

Niu X, Roche L, Pawlish K, Henry K . Cancer survival disparities by health insurance status. Cancer Med. 2013; 2(3):403-11. PMC: 3699851. DOI: 10.1002/cam4.84. View

20.

Fossati N, Nguyen D, Trinh Q, Sammon J, Sood A, Larcher A . The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer. J Natl Compr Canc Netw. 2015; 13(11):1351-8. DOI: 10.6004/jnccn.2015.0164. View